MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Cough medicine ingredient could treat prostate cancer

Back to prostate cancer blog Blogs list Cancer blog  


Subscribe To Prostate Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Cough medicine ingredient could treat prostate cancer




A study published recently in the recent issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer. Scientists observed that noscapine, which has been used in cough medicine for nearly 50 years, reduced tumor growth in mice by 60% and limited the spread of tumors by 65% without causing harmful side effects.

Prostate cancer is the most common cancer among men in the United States. The American Cancer Society estimates that 186,320 men will be diagnosed with prostate cancer in 2008 and 28,660 will die from it. One man in 6 will get prostate cancer during his lifetime. Eventhough slow-growing in most men, the cancer is considered advanced when it spreads beyond the prostate. There is no known cure.



Cough medicine ingredient could treat prostate cancer

The laboratory study was a joint effort by Dr. Israel Barken of the Prostate Cancer Research and Educational Foundation, Moshe Rogosnitzky of MedInsight Research Institute, and Dr. Jack Geller of The University of California San Diego. Noscapine has previously been studied as a therapy for breast, ovarian, colon, lung and brain cancer and for various lymphomas, chronic lymphocytic leukemia and melanoma. This study, however, is the first to demonstrate its effectiveness in treating prostate cancer.

Noscapine is a naturally-occurring substance, a non-addictive derivative of opium. As a natural substance, noscapine cannot be patented, which has limited the potential for clinical trials. Rogosnitzky notes that drug companies are generally unwilling to underwrite expensive clinical trials without being able to recoup their investment. A synthetic derivative of noscapine has been patented but has still not reached the clinical testing phase.

Since noscapine is approved for use in a number of countries as a cough suppressant, however, it is available to doctors to prescribe for other uses as well. This common practice is known as "off-label" prescription. Noscapine is increasingly being used off-label to treat a variety of cancers. Dr. Barken used noscapine to treat a handful of patients with prostate cancer before retiring from clinical practice. Encouraged by the success of these therapys, his foundation funded the laboratory study being published in the December 2008 edition of Anticancer Research
As founder and medical director of the Prostate Cancer Research and Educational Foundation in San Diego, Dr. Barken is encouraging academic institutions to follow up this successful laboratory research with a human clinical trial. He has pioneered a web-based patient tracking system that will greatly reduce the cost of the trial while cutting the time necessary to complete the study. Using the web-based tracking system will also allow doctors outside the U.S. to enroll patients in the research.

Rogosnitzky, director of research at MedInsight Research Institute, points out the significant advantages that noscapine could present as a therapy for prostate cancer. "Noscapine is effective without the unpleasant side effects linked to other common prostate cancer therapys. Because noscapine has been used as a cough-suppressant for nearly half a century, it already has an extensive safety record. This pre-clinical study shows that the dose used to effectively treat prostate cancer in the animal model was also safe".

Hormone treatment and chemotherapy, along with radiation and surgery, are currently used to slow the progression of advanced prostate cancer. Side effects resulting from these therapys include impotence, incontinence, fatigue, anemia, brittle bones, hair loss, reduced appetite, nausea and diarrhea. No toxic side effects were observed in the laboratory study of noscapine.


Posted by: Mark    Source




Did you know?
A study published recently in the recent issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer. Scientists observed that noscapine, which has been used in cough medicine for nearly 50 years, reduced tumor growth in mice by 60% and limited the spread of tumors by 65% without causing harmful side effects.

Medicineworld.org: Cough medicine ingredient could treat prostate cancer

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.